Nature Reviews Gastroenterology & Hepatology

Papers
(The H4-Index of Nature Reviews Gastroenterology & Hepatology is 69. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)
ArticleCitations
Regulating protease homeostasis in irritable bowel syndrome855
Zolbetuximab treatment in metastatic gastric cancer582
Immunosuppressive IBD drugs and COVID-19 vaccine immunogenicity575
Hybrid EASL Congress 2023564
Celebrating 20 years of Nature Reviews Gastroenterology & Hepatology523
Unlocking CD8+ T cell potential in chronic hepatitis B virus infection489
Mirikizumab for inducing and maintaining clinical remission in ulcerative colitis467
Author Correction: Towards unifying fatty liver nomenclature: a voice from the Middle East and North Africa417
Mapping neuroimmune interactions in the gut411
Digestive Disease Week 2022385
Western lifestyle, metaflammation and the cell of origin of colon cancer367
2023 FDA approvals in gastroenterology and hepatology343
Advancing nutrition science for global health276
Black–White disparities across the colorectal cancer care continuum in the USA265
New potent HBV replication inhibitors for the management of chronic hepatitis B are needed262
The future of treating pancreatic exocrine insufficiency253
Nomenclature of HBV core protein-targeting antivirals242
Large language models for clinical decision support in gastroenterology and hepatology225
Artificial intelligence and automation in endoscopy and surgery225
Helicobacter pylori, microbiota and gastric cancer — principles of microorganism-driven carcinogenesis208
The role of the enteric nervous system in the pathogenesis of Clostridioides difficile infection207
Oral microbiome therapy efficacious for recurrent C. difficile infection204
Wound healing in the colon198
Hepatic IRF3 in glucose intolerance192
New understanding of hepatobiliary MRI187
Metastatic pancreatic cancer and the liver182
GWAS reveals variants for alcohol-related hepatocellular carcinoma181
Lessons from incretin-based therapy in MASH and obesity180
Food as medicine in gastrointestinal cancer therapy172
The global burden of coeliac disease: opportunities and challenges168
CAR T cell therapies in gastrointestinal cancers: current clinical trials and strategies to overcome challenges167
A crucial Fusobacterium nucleatum clade in colorectal cancer165
Inflammatory bowel disease in pregnancy and breastfeeding153
Novel insights into chronic HBV infection150
The gut–brain axis and pain signalling mechanisms in the gastrointestinal tract142
A greener gastroenterology: challenges and opportunities for an eco-sustainable approach to digestive diseases141
The changing metabolic landscape of bile acids – keys to metabolism and immune regulation141
Hepatocyte-derived biomarkers in alcohol-related cirrhosis139
Characterizing the genomic landscape of colorectal cancer137
Integrated systems approach to identify environmental factors in intestinal inflammation137
Estimating dietary intake from human stool DNA136
HDCA ameliorates NAFLD in mice135
The path to successful hepatitis C elimination in Spain133
SSRIs and depression: role of gut–brain communication128
Author Correction: Μetabolic dysfunction-associated steatotic liver disease: a condition of heterogeneous metabolic risk factors, mechanisms and comorbidities requiring holistic treatment125
Human intestinal B cells in inflammatory diseases125
Probiotics for preterms: sharing complex decision-making121
Implications of the evolving knowledge of the genetic architecture of MASLD120
Medical therapy of paediatric inflammatory bowel disease115
Metabolic diseases in the East Asian populations113
Liver, ageing and disease113
Preventing the progression of cirrhosis to decompensation and death109
A roadmap for serum biomarkers for hepatitis B virus: current status and future outlook107
Clinical trial design, biomarkers and end points in metabolic and alcohol-related liver disease106
Current and future colorectal cancer screening strategies105
Proteases in intestinal health and disease104
Irritable bowel syndrome and mental health comorbidity — approach to multidisciplinary management100
NAFLD prevalence in older patients with T2DM97
Phase III results for first-line treatment for metastatic colorectal cancer93
Author Correction: Hepatic immune regulation and sex disparities90
ECCO’2486
The future of pathology in gastroenterology and hepatology85
Microbiota and colorectal cancer — controlling for confounders challenges associations85
GLP1R agonists in NAFLD: a promising therapy on the horizon83
Enteric nervous system transfers stress to the gut83
Reply to ‘Incorporating genetic variations in alcohol-associated liver disease trials for East Asian populations’83
Transforming the landscape of liver cancer detection and care78
Neutrophils as potential therapeutic targets in hepatocellular carcinoma73
Risk minimization of JAK inhibitors in ulcerative colitis following regulatory guidance73
Hepatic inflammatory responses in liver fibrosis69
0.17802691459656